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Oxaliplatin, an anti-cancer chemotherapeutic agent used for the treatment of colorectal
cancer, commonly causes gastrointestinal side-effects such as constipation, diarrhoea,
nausea, and vomiting. Damage to enteric neurons may underlie some of these
gastrointestinal side-effects, as the enteric nervous system (ENS) controls functions of
the bowel. In this study, neuronal loss and changes to the structure and immunoreactivity
of myenteric neuronal nitric oxide synthase (nNOS) neurons were examined in colonic
segments from mice following exposure to oxaliplatin ex vivo and following repeated
intraperitoneal injections of oxaliplatin over 3 weeks in vivo, using immunohistochemistry
and confocal microscopy. Significant morphological alterations and increases in the
proportion of NOS-immunoreactive (IR) neurons were associated with both short-term
oxaliplatin exposure and long-term oxaliplatin administration, confirming that oxaliplatin
causes changes to the myenteric neurons. Long-term oxaliplatin administration induced
substantial neuronal loss that was correlated with a reduction in both the frequency
and propagation speed of colonic migrating motor complexes (CMMCs) in vitro.
Similar changes probably produce some symptoms experienced by patients undergoing
oxaliplatin treatment.
Keywords: chemotherapy, enteric neuropathy, oxaliplatin, neurotoxicity, nitric oxide synthase (NOS), colon
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INTRODUCTION
Oxaliplatin, a third-generation platinum drug, has become one
of the first-line therapies used in the treatment of metastatic col-
orectal cancer (de Gramont et al., 2000; Petrioli et al., 2008).
Commonly administered in combination with 5-fluorouracil and
leucovorin, oxaliplatin has been shown to improve response rates
and survival of patients (André et al., 2004), and has anti-tumor
activity against some cancer cell lines resistant to first-generation
(cisplatin) and second-generation (carboplatin) platinum drugs
(Machover et al., 1996; Louvet et al., 2002; Raymond et al., 2002).
Although oxaliplatin is widely used clinically, there remains a
poor understanding of its mechanisms of action. Oxaliplatin is
known to be activated by non-enzymatic hydrolysis and dis-
placement of the oxalate ligand, which forms highly reactive
compounds that react with proteins, RNA, and DNA, specifi-
cally nuclear DNA, whereas mitochondrial DNA is less affected
(Woynarowski et al., 1998; Kweekel et al., 2005). Like cisplatin,
oxaliplatin preferentially binds to guanine clusters to mainly form
intrastrand crosslinks (Woynarowski et al., 1998; Hector et al.,
2001; Fuertes et al., 2003; Kweekel et al., 2005; Wang and Lippard,
2005). The platinum-DNA adducts formed are believed to inhibit
DNA replication and transcription and to induce apoptosis or
necrosis in cancer cells and rapidly dividing cell lines (Fuertes
et al., 2003; Kweekel et al., 2005).
A frequent complication associated with chemotherapeutic
agents is toxicity, which poses an imperative obstacle in the
treatment of cancer patients, as doses of chemotherapy are
consequently limited. Oxaliplatin toxicity is distinct from that
produced by other platinum drugs, with very little hemato-
toxicity and no renal toxicity (de Gramont et al., 2000). The
most common adverse effects due to oxaliplatin-induced tox-
icity include peripheral neurotoxicity (acute and persistent),
ototoxicity, weight loss, fatigue, and gastrointestinal symptoms
such as nausea, vomiting, constipation, and diarrhoea (Visovsky,
2003; Leonard et al., 2005). The gastrointestinal symptoms often
appear shortly after treatment (acute toxicities) or long after
treatment (late toxicities), with a subsequent period of toxicity
ranging from months to years (Di Fiore and Van Cutsem, 2009).
Although the gastrointestinal symptoms are widely acknowl-
edged as adverse effects of platinum-based chemotherapeutic
drugs, research into their underlying mechanism is scarce. It
is known that platinum compounds have a high affinity for
the peripheral nervous system (PNS) (Cavaletti et al., 2001;
McDonald et al., 2005), and there is a possibility that these
compounds may also react within the enteric nervous system
(ENS), which is the largest and most complex subdivision of
the PNS.
The ENS is located within the wall of the gastrointestinal
tract and responsible for its physiological functions such as secre-
tion, blood flow, and motility (Furness et al., 2008; Burzynski
et al., 2009). Damage to enteric neurons, or changes in their
electrophysiological properties, results in altered and deficient
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physiological functions of the gut which has been demonstrated
in studies of intestinal inflammation (Linden et al., 2003; Lomax
et al., 2007; Nurgali et al., 2007, 2011). Deficient physiological
functions have also been demonstrated as a result of damage
to neurons in the ENS of rats following long-term cisplatin
administration. Marked reductions in both gastrointestinal tran-
sit rate and colonic motor activity were observed, alongside a
significant decrease in the number of neurons per ganglion,
and an increase in the proportion of nitric oxide synthase-
immunoreactive (NOS-IR) neurons in themyenteric plexus of the
rat colon (Vera et al., 2011). Intriguingly, an upregulation of neu-
ronal NOS (nNOS) has also been reported in the spinal cord of
rats following repeated oxaliplatin administration (Mihara et al.,
2011).
The nNOS enzyme is responsible for the synthesis of the
free-radical gas nitric oxide (NO), which mediates inhibitory
neuromuscular transmission within the gastrointestinal tract and
may also have roles in the enteric neural circuits themselves (Yuan
et al., 1995; Dickson et al., 2007; Bornstein et al., 2010). Changes
to neurons expressing nNOS have been linked to a number of
enteric neuropathies, some of which include colonic dysfunction
associated with diabetes and ischemia of the intestine (Furness,
2006; Rivera et al., 2011).
In this study, we investigated the effects of both ex vivo tissue
culture with oxaliplatin, and the effects of short- and long-term
repeated in vivo oxaliplatin administration on the myenteric neu-
rons of the mouse colon. In particular, we aimed to determine the
nature of oxaliplatin-induced changes to the myenteric neurons
by examining neuronal loss and nNOS expression. Moreover,
we studied the effects of in vivo oxaliplation administration on
spontaneous motor activity of the mouse colon.
MATERIALS AND METHODS
ANIMALS
Male Balb/c mice aged 5–8 weeks (18–25 g) were used in this
study. Mice were supplied from the Animal Resources Centre
(WA, Australia). Animals were kept on a 12 h light and dark
cycle at ∼22◦C with free access to food and water. The mice were
allowed to acclimatize for at least 1 week following arrival.
All procedures in this study were approved by the Victoria
University Animal Experimentation Ethics Committee and per-
formed in accordance with the guidelines of the National Health
and Medical Research Council.
Ex vivo TISSUE CULTURE
Control Balb/c mice were euthanized by cervical dislocation
on the day of the experiment and the distal colon seg-
ments were removed for ex vivo tissue culture with oxali-
platin (Sigma-Aldrich, Australia). Tissues were grouped into
(1) control, (2) low concentration oxaliplatin (10 nM), and
(3) high concentration oxaliplatin (10μM). All colon seg-
ments were pinned onto a silicon base dish and incubated
in oxygenated (95% oxygen, 5% carbon dioxide) Dulbecco’s
Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, Australia)
containing 10% foetal bovine serum (Invitrogen, Australia), 1%
antibiotic/antimycotic solution (comprising penicillin, strepto-
mycin, and amphotericin) (complete DMEM) (Sigma-Aldrich,
Australia), along with the respective dose of oxaliplatin for a
period of 3 and 24 h. During incubation, the dishes contain-
ing the distal colon segments were kept constantly shaking on
a Unimax-1010 platform shaker (Heidolph, Germany) under
sterile conditions at 37◦C using an Incubator-1000 (Heidolph,
Germany). Following incubation, tissues were then cut open
along the mesenteric border, maximally stretched and pinned
mucosa up into the same dish, before being fixed overnight at 4◦C
with Zamboni’s fixative containing 2% formaldehyde and 0.2%
picric acid.
In vivo OXALIPLATIN INJECTIONS
Mice were grouped into (1) oxaliplatin-treated and (2) sham-
treated cohorts. The mice from group 1 received intraperitoneal
injections of oxaliplatin (3mg/kg) three times a week with 26
gauge needles, and mice from group 2 were injected with sterile
water. Mice were euthanized by cervical dislocation at the end of
the experimental period (3, 7, 14, and 21 days). Segments of the
distal colon were removed and placed in oxygenated phosphate-
buffered saline (PBS, pH 7.2) containing the L-type Ca2+ channel
blocker nicardipine (3μM) for 20min before being cut open
along the mesenteric border,maximally stretched and pinned into
a silicon base dish. Tissues were then fixed with Zamboni’s fixative
overnight at 4◦C.
IMMUNOHISTOCHEMISTRY
Fixed tissues were washed three times for 10min each with
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Australia) followed
by three 10min washes with PBS. Tissues were then dis-
sected to expose the myenteric plexus by removing the mucosa,
submucosa, and circular muscle layers. Tissues were incu-
bated for 1 h at room temperature with 10% normal donkey
serum (Millipore, MA, USA). Myenteric neurons were double
labeled in these wholemount preparations with primary anti-
bodies raised in different species: anti-β-Tubulin class III, TuJ1
(Rabbit, 1:2000, Abcam, MA, USA), anti-nNOS (Goat, 1:500,
Novus Biologicals, CO, USA) overnight at 4◦C. Tissues were
washed three times for 10min with PBS before incubation
with species-specific secondary antibodies labeled with differ-
ent flurophores: Donkey anti-rabbit Alexa 488 and 594 (1:200,
Invitrogen, VIC, Australia), Donkey anti-goat FITC (1:200,
Jackson Immunoresearch Laboratories, PA, USA) for 2 h at room
temperature. Tissues were given a further three 10min washes
with PBS, followed by a 2min incubation with the fluores-
cent nucleic acid stain 4′-6-diamidino-2-phenylindole (DAPI)
(14 nM) (Invitrogen, Australia). Tissues received one final 10min
PBS wash before being mounted onto glass slides with fluorescent
mounting medium (DAKO, Australia).
IMAGING
Three-dimensional (z-series) images of the wholemount prepa-
rations were taken using an Olympus FluoView FV1000 confocal
laser scanning microscope (Olympus, Australia). Fluorophores
were visualized using excitation filters for Alexa 594 and
Rhodamine Red (excitation wavelength 559 nm), Alexa 488 and
FITC (excitation wavelength 473 nm), and DAPI (excitation
wavelength 405 nm). Z-series images were taken at a stepsize of
1.75μm (1600 × 1200 pixels).
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NEURONAL CELL COUNTING
The wholemount preparations were observed under a fluorescent
microscope Olympus BX53 (Olympus, Australia). Each prepa-
ration was analysed by randomly capturing four images at 20×
magnification using a DP72 camera and processed by cellSens
Standard 1.4.1 software (Olympus, Australia). The total num-
ber of neurons per 2mm2 area was quantified by counting
TuJ1-positive cells with round or oval shape nuclei counter-
stained with DAPI within the ganglia. NOS immunoreactivity
was quantified by counting the number of nNOS positive neu-
rons within the same area. Data were obtained from three ani-
mals per time point (ex vivo: 3 and 24 h; in vivo: 3, 7, 14, and
21 days).
NEURONAL MEASUREMENT
The total area of individual NOS-IR neurons (μm2), including
dendrites, was measured by tracing neuronal profiles using Image
J software (NIH, MD, USA). The cohort size was 30 neurons
per animal. Data were obtained from three animals per time
point (3, 7, 14, and 21 days) for both oxaliplatin-treated and
sham-treated groups.
COLONIC MOTILITY EXPERIMENTS
The entire colon (5–6 cm) was removed from control, Day 14
sham, and Day 14 oxaliplatin-treated animals (n = 5 per each
group) and set up to allow spatiotemporal maps to be made of
spontaneous motor patterns in vitro (Roberts et al., 2007, 2008).
Briefly, the colon was left in physiological saline (composition
in mM: NaCl 118, KCl 4.6, CaCl2 3.5,MgSO4 1.2, NaH2PO4 1,
NaHCO3 25, d-Glucose 11, oxygenated with 95% O2 and 5%
CO2), until the faecal pallets were expelled. The empty colon
was cannulated at both ends and set up horizontally in organ
bath chambers superfused with oxygenated physiological saline
and kept at a constant temperature of 35◦C. The oral cannula
was connected to a reservoir-containing oxygenated physiological
saline. The intraluminal pressure of the segment was maintained
at +2 cm H2O, by adjusting the height of a reservoir connected
to the oral cannula. The anal end was connected to an out-
flow tube that provided a maximum of 2 cm H2O back-pressure.
Contractile activity of each segment was recorded with a Logitech
Quickcam pro camera positioned 7–8 cm above the preparation.
Following a 30min equilibration period, four 15min videos were
captured. Videos were then used to construct spatiotemporal
maps of the diameter at each point along the segment using in
house software (Gwynne et al., 2004). Spatiotemporal maps were
used to quantify the frequency and propagation speed of colonic
migrating motor complexes (CMMCs), defined as constrictions
that propagate for at least 50% of the length of the colon (Roberts
et al., 2007, 2008).
STATISTICAL ANALYSIS
Data were assessed using a Two-Way ANOVA followed by a
Bonferroni’s post-hoc test. Analyses were performed using Graph
Pad Prism (Graph Pad Software Inc., CA, USA). All data
are presented as mean ± standard error of the mean (SEM).
Value differences were considered statistically significant at
P < 0.05.
RESULTS
EFFECTS OF LOW AND HIGH OXALIPLATIN CONCENTRATIONS ON
MYENTERIC NEURONS IN TISSUE CULTURE
To determine the effects of oxaliplatin on myenteric neurons at
various concentrations, ex vivo distal colon segments were cul-
tured with either a low (10 nM) or a high concentration (10μM)
of oxaliplatin for 3 and 24 h.
After 3 h in culture, a notable increase in the proportion of
NOS-IR myenteric neurons per area (2mm2) was detected in the
tissues incubated with both the low dose of oxaliplatin (20.7 ±
1.4%, P < 0.05) and the high dose of oxaliplatin (21.7 ± 0.7%,
P < 0.001) in comparison to the control group (17.1 ± 0.5%)
(Figure 1A). A significantly increased proportion of NOS-IR
myenteric neurons was also seen following 3 h in culture with
a high concentration of oxaliplatin per 2mm2 (control: 127.3 ±
13.9; high dose: 170.7 ± 16.2, P < 0.05). After 24 h in culture, the
high dose oxaliplatin group also displayed a higher proportion of
NOS-IR myenteric neurons than controls (control: 12.4 ± 0.5%;
high dose: 14.8 ± 0.3%, P < 0.05) (Figure 1A).
EFFECTS OF REPEATED in vivo OXALIPLATIN ADMINISTRATION ON
MYENTERIC NEURONS
To determine whether the changes induced by oxaliplatin in the
ex vivo tissue culture also occur in in vivo, the effects of repeated
short- and long-term oxaliplatin administration were examined
(Figures 2A,B).
The total number of myenteric neurons was significantly
reduced in the oxaliplatin-treated group when compared to
the sham-treated group at Day 14 (sham-treated: 970 ± 46;
oxaliplatin-treated: 726 ± 15, P < 0.05) and at Day 21 (sham-
treated: 907 ± 67; oxaliplatin-treated: 629 ± 30, P < 0.01). A
comparison within the oxaliplatin-treated group alone also shows
a substantial reduction in the number of neurons from Day 3
(1007 ± 50) to Days 14 (726 ± 15, P < 0.001) and 21 (629 ± 30,
P < 0.001) (Figure 1B).
Consistent with the ex vivo tissue culture, wholemount prepa-
rations of the distal colon from in vivo oxaliplatin-treated mice
displayed a substantial increase in the proportion of NOS-IR
myenteric neurons at all four time points following treatment
(Day 3: 23.7 ± 0.4%; Day 7: 23.2 ± 0.7%; Day 14: 22.3 ± 0.4%;
and Day 21: 23.6 ± 1.2%) in comparison to the sham-treated
group (Day 3: 20.6 ± 0.8%; Day 7: 17.8 ± 0.7%; Day 14: 19.7 ±
0.5%; and Day 21: 18.7 ± 1.1%, P < 0.05) (Figure 1C).
MORPHOLOGICAL CHANGES IN NOS-IMMUNOREACTIVE NEURONS
The morphology of the NOS-IR myenteric neurons was exam-
ined in the in vivo sham-treated and oxaliplatin-treated groups to
determine if oxaliplatin administration produced changes to the
neuronal shape and size.
NOS-IR myenteric neurons in wholemount preparations of
the distal colon from the oxaliplatin-treated mice appear to be
larger, with more prominent and distorted dendrites at all four
time-points (Day 3, 7, 14, and 21) in comparison to the sham-
treated group (Figure 3).
Measurements of the profile of NOS-IR neurons verified
that total neuronal area, including dendrites, was significantly
increased at all four time-points in the oxaliplatin-treated group
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FIGURE 1 | In vitro and in vivo effects of oxaliplatin on the myenteric
neurons in the mouse distal colon. (A) A significant increase in the
proportion of NOS-IR neurons per area (2mm2) within the myenteric
plexus of the distal colon cultured with a high concentration of oxaliplatin
compared to the control at both 3 (∗∗∗P < 0.001) and 24 h (∗P < 0.05) and
a low concentration of oxaliplatin at 3 h of tissue culture (∗P < 0.05).
(B) A significant decrease in the total number of myenteric neurons at
both Day 14 and Day 21 following in vivo oxaliplatin administration
compared to the sham-treated at the same time points (∗P < 0.05) and
Day 3 oxaliplatin-treated mice (∗∗∗P < 0.001). (C) Proportion of
NOS-immunoreactive neurons per area (2mm2) within the myenteric
plexus of the distal colon was significantly increased at all four time-points
(Days 3, 7, 14, and 21) following in vivo oxaliplatin administration compared
to the sham-treated mice (∗∗∗P < 0.001). All data represent the
mean ± SEM.
(Day 3: 466 ± 17μm2; Day 7: 470 ± 20μm2; Day 14: 479 ±
14μm2; and Day 21: 509 ± 20μm2) when compared to the
sham-treated group (Day 3: 251 ± 4μm2; Day 7: 250 ± 11μm2;
Day 14: 253 ± 14μm2; and Day 21: 260 ± 10μm2, P < 0.001)
(Figure 4).
CHANGES IN COLONIC MOTILITY
To identify functional consequences of the anatomical changes
produced by oxaliplatin, video-recordings of colonic motor activ-
ity were used to construct spatiotemporal maps of CMMCs, a
repetitive stereotyped motor pattern characteristic of the iso-
lated mouse colon (e.g., Roberts et al., 2007, 2008). Analysis of
maps from Day 14 oxaliplatin-treated mice showed a significant
decrease in both frequency (0.6 ± 0.07 per min) and propagation
speed (3.1 ± 0.4mm/s) of CMMCs compared to sham-treated
(frequency of contractions: 1.2 ± 0.14 per min, P < 0.05; speed:
4.8 ± 4mm/s, P < 0.05) and control groups (frequency of con-
tractions: 1.1 ± 0.1 per min, P < 0.05; speed: 4.8 ± 0.3mm/s,
P < 0.05) (Figure 5).
DISCUSSION
This study is the first to examine the effects of oxaliplatin on the
myenteric neurons in a mouse model of chemotherapy. Numbers
and nNOS-IR of myenteric neurons were compared under two
conditions: (1) ex vivo tissue culture with oxaliplatin for 3 and
24 h; and (2) repeated in vivo oxaliplatin administration into mice
for up to 3 weeks. This allowed some neurotoxic effects of oxali-
platin on enteric neurons over short and extended periods of
oxaliplatin administration to be evaluated and correlated with
chronic oxaliplatin effects on colonic motility, in vitro.
Our major findings are consistent with an earlier study of
the effects of cisplatin on rat enteric neurons (Vera et al., 2011).
Like cisplatin in rats, oxaliplatin in mouse causes a proportional
increase of NOS-IR neurons and a significant reduction in the
total number of myenteric neurons. The decrease in numbers of
neurons correlates with a reduction in CMMC frequency, some-
thing seen previously in mouse models of Hirschsprung disease
(Roberts et al., 2008).
Dorsal root ganglion (DRG) neurons undergo apoptosis fol-
lowing exposure to oxaliplatin (Ta et al., 2006; Scuteri et al., 2009)
and oxaliplatin accumulation in DRG neurons have been found
(Holmes et al., 1998; Cavaletti et al., 2001; Ta et al., 2006). This
has been proposed as the underlying cause of oxaliplatin-induced
sensory neuropathy (Gill andWindebank, 1998). Platinum-based
chemotherapeutic agents are designed to target and destroy pro-
liferating cancer cells; but these agents also damage neurons,
which are differentiated and non-proliferative. It has been sug-
gested that platinum compounds may cause neurons to unsuc-
cessfully re-enter the cell cycle (Gill andWindebank, 1998), as cell
cycle protein expression is altered following exposure to cisplatin
(Gill and Windebank, 1998; McDonald et al., 2005). Platinum-
induced apoptosis has also been associated with the involvement
of the mitogen-activated protein kinases (MAPK) family (Scuteri
et al., 2009), which are responsible for regulating a number of cel-
lular activities such as differentiation, proliferation, and cell death
(Lewis et al., 1998). In particular, the extracellular signaling-
regulated kinase (ERK 1/2) and p38, which have well-recognized
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FIGURE 2 | (A) Wholemount preparations of the myenteric neurons in the
distal colon segments following 3 (2a–2d) and 7 (4a–4d) days of repeated
in vivo oxaliplatin administration compared to sham-treated animals at 3
(1a–1d) and 7 (3a–3d) days. Myenteric ganglia and neurons labeled with
β-Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen
within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with
DAPI (1b). Significant increase in the proportion of NOS neurons
(Continued)
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FIGURE 2 | Continued
(green) can be seen at both Days 3 and 7 after oxaliplatin treatment. Scale
bar = 20μm. (B) Wholemount preparations of the myenteric neurons in
the distal colon segments following 14 (2a–2d) and 21 (4a–4d) days of
repeated in vivo oxaliplatin administration compared to sham-treated
animals at 14 (1a–1d) and 21 (3a–3d) days. The reduction in total number
of neurons and increase in the proportion of NOS neurons was found at
both Days 14 and 21 after oxaliplatin treatment. Scale bar = 20μm.
FIGURE 3 | Morphological changes in myenteric NOS-IR neurons
following repeated intraperitoneal administration of oxaliplatin.
Neurons from mice receiving oxaliplatin from Days 3 to 21 (C–F) display
an increase in the soma size and prominent, slightly distorted dendrites
(arrows) when compared to the neurons from the sham-treated mice
(A,B). Scale bar = 10μm.
FIGURE 4 | Effects of repeated in vivo oxaliplatin administration on the
total area of NOS-IR neurons (μm2) within the myenteric plexus of the
distal colon segments. Data represent the mean ± SEM. A significant
increase in the total area of neurons immunoreactive to NOS was
observed at all four time points (Day 3, 7, 14, and 21), following oxaliplatin
administration in comparison to the sham-treated mice (∗∗∗P < 0.001).
roles in neuronal apoptosis, have displayed early activation in
DRG neurons following exposure to both oxaliplatin and cisplatin
(Takeda and Ichijo, 2002; Scuteri et al., 2009).
Although the mechanisms of platinum-induced neuronal
death have yet to be studied in enteric neurons, it has
been speculated that the death of sensory DRG neurons
involves afferent neurons innervating the gastrointestinal tract
(Vera et al., 2011). However, the extent of neuronal loss
seen in our study suggests that oxaliplatin might also induce
apoptosis of myenteric neurons which needs to be further
studied. The death of enteric neurons is associated with
impairment of colonic motility observed in our study and
in a previous study with cisplatin (Vera et al., 2011), which
may explain some gastrointestinal symptoms experienced by
patients.
Further oxaliplatin-induced changes to myenteric neurons in
this study included the significant increase in the proportion
of NOS-IR neurons both ex vivo and in vivo. NOS, and in
particular nNOS, seems to play a significant role in oxaliplatin-
induced neurotoxicity. This is noteworthy, as nNOS is typically
expressed by interneurons and inhibitory motor neurons that
supply the circular and longitudinal muscles of the gastrointesti-
nal tract (Bornstein et al., 2004). A recent study has shown that
the repeated administration of oxaliplatin in the rat causes an
upregulation of nNOS in the spinal cord (Mihara et al., 2011).
This finding has been associated with the incidence of mechanical
allodynia, the sensation of pain caused by a stimulus that would
not normally produce pain, e.g., light touch or cold. The admin-
istration of both selective and non-selective NOS inhibitors pre-
vented the pain behavior initially seen in rats following oxaliplatin
administration.
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FIGURE 5 | Effects of in vivo oxaliplatin treatment on propulsive
activity of the colon. Spatiotemporal maps of the colon (A) from
control, Day 14 sham-treated, and Day 14 oxaliplatin-treated mice.
Anally propagating contractions that begin at the oral end of the
preparation and continue to the anal end can be readily seen as red
areas (arrows) separated by periods of quiescence. Frequency of
contractions (B) and propagation speed (C) decreased significantly in
the colon from Day 14 oxaliplatin-treated mice compared to both
sham-treated and control groups (∗P < 0.05 for all). Data represent
the mean ± SEM.
The production of NO by nNOS depends on levels of
cytoplasmic Ca2+. When cytoplasmic Ca2+ is elevated, nNOS
is activated, possibly leading to excessive NO production, which
causes cell damage (Yagihashi et al., 2000), and may account for
the oxaliplatin-induced increase in NOS-IR neuron size seen in
this study. This needs to be further investigated. Elevated cyto-
plasmic Ca2+ is also known to cause cytotoxic damage to neurons
and can trigger apoptosis (Rivera et al., 2011).
Conversely, the increased proportion of NOS-IR neurons seen
with oxaliplatin administration in our study could partly be
due to the loss of other subpopulations of myenteric neurons.
Therefore, these results could be due to a combination of both
increases in cytoplasmic Ca2+ and free-radical NO, and the death
of other neuronal subgroups within the ENS. It is also possi-
ble that NOS-IR neurons are capable of better survival following
oxaliplatin administration than other subgroups of myenteric
neurons, as nNOS neurons have been shown to remain quite
resistant to toxicities in Alzheimer’s disease, Huntington’s dis-
ease, and vascular stroke (Gonzalez-Zulueta et al., 1998). Recent
study in nNOS knockout mice has shown that NO produced by
nNOS has protective effects on enteric neurons following intesti-
nal ischemia/reperfusion injury (Rivera et al., 2012). Further
studies need to be carried out investigating the mechanisms
by which oxaliplatin-induced changes occur in the enteric neu-
rons and determining which subpopulations are being affected.
The effect of oxaliplatin on enteric neuron function also needs
to be examined, including changes in the electrophysiologi-
cal properties of neurons, neurotransmission, and ion chan-
nel functions.
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